SPOTLIGHT: Avexa gains rights to HIV drug


Shire has licensed the North American rights to the HIV compound SPD754 to Australia's Avexa in exchange for an up front payment of $10 million and sales and development milestones. Shire gets eight million shares of Avexa in the deal, boosting its stake in the company to eight percent. Release | Report

Suggested Articles

Bristol Myers Squibb may have bounced Jounce from its roster of inherited partners, but it’s hanging onto Anokion, a Swiss autoimmune-focused biotech.

The priority review action date sets Bristol Myers up to win approval for the bluebird-partnered anti-BCMA CAR-T therapy in late March.

The unidentified biotechs are drawn from the portfolio of a €150 million life science-focused fund that Index Ventures set up.